TY - JOUR
T1 - Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma
T2 - no ordinary subgroup analysis
AU - Russler-Germain, David A.
AU - Cliff, Edward R.Scheffer
AU - Bartlett, Nancy L.
N1 - Publisher Copyright:
© 2023 The American Society of Hematology
PY - 2023/12/21
Y1 - 2023/12/21
N2 - Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.
AB - Subgroup analysis from the POLARIX trial of polatuzumab vedotin plus chemotherapy for untreated large B-cell lymphoma suggests greater efficacy among patients with activated B-cell subtype disease. Both preclinical and additional clinical evidence support this interaction between cell-of-origin and polatuzumab efficacy.
UR - http://www.scopus.com/inward/record.url?scp=85175344626&partnerID=8YFLogxK
U2 - 10.1182/blood.2023022048
DO - 10.1182/blood.2023022048
M3 - Article
C2 - 37797275
AN - SCOPUS:85175344626
SN - 0006-4971
VL - 142
SP - 2216
EP - 2219
JO - Blood
JF - Blood
IS - 25
ER -